» Articles » PMID: 36756098

A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas

Abstract

Supriya Mallick  Malignant gliomas are the most common primary malignant brain tumors and are typically treated with maximal safe surgical resection followed by chemoradiation. One of the unintended effects of radiation is depletion of circulating lymphocyte pool, which has been correlated with inferior overall survival outcomes.  A comprehensive and systematic searches of the PubMed, Cochrane Central, and Embase databases were done to assess the studies that have reported radiation-related lymphopenia in high-grade gliomas. Hazard ratios (HRs), odds ratios (OR), and mean differences were represented with Forest plots comparing patients with severe lymphopenia and no severe lymphopenia. Review Manager Version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for the analysis.  Nineteen studies were included in the final systematic review and 12 studies were included in the meta-analysis. The odds of developing severe lymphopenia were 0.39 (95% CI:0.19, 0.81,  = 94%,  = 0.01). Patients with severe lymphopenia were at increased risk of death with a pooled HR = 2.19 (95% CI: 1.70, 2.83,  = 0%, <0.00001) compared to patients with no severe lymphopenia. The mean difference in survival between patients with severe lymphopenia and no severe lymphopenia was -6.72 months (95% CI: -8.95, -4.49,  = 99%, <0.00001), with a better mean survival in the no severe lymphopenia group.  Radiation-induced severe lymphopenia was associated with poor overall survival and increased risk of death. Photon therapy, larger planning target volume, higher brain dose, higher hypothalamus dose, and female gender were associated with increased risk of severe lymphopenia.

Citing Articles

Impact of intensity-modulated proton therapy in reducing radiation-induced lymphopenia in glioma patients.

Das A, Sylvia J, Krishnan G, Panda P, Subramanyam P, Kumar R Neurooncol Adv. 2024; 6(1):vdae088.

PMID: 39045310 PMC: 11263926. DOI: 10.1093/noajnl/vdae088.


How proton therapy fits into the management of adult intracranial tumors.

Kotecha R, La Rosa A, Mehta M Neuro Oncol. 2024; 26(12 Suppl 2):S26-S45.

PMID: 38437667 PMC: 10911801. DOI: 10.1093/neuonc/noad183.


The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.

Stepanenko A, Sosnovtseva A, Valikhov M, Chernysheva A, Abramova O, Naumenko V Front Immunol. 2024; 15:1326757.

PMID: 38390330 PMC: 10881776. DOI: 10.3389/fimmu.2024.1326757.

References
1.
Kmiecik J, Poli A, Brons N, Waha A, Eide G, Enger P . Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013; 264(1-2):71-83. DOI: 10.1016/j.jneuroim.2013.08.013. View

2.
Campian J, Sarai G, Ye X, Marur S, Grossman S . Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2013; 36(12):1747-53. PMC: 4081494. DOI: 10.1002/hed.23535. View

3.
Mendez J, Govindan A, Leong J, Gao F, Huang J, Campian J . Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol. 2016; 127(2):329-35. PMC: 4783226. DOI: 10.1007/s11060-015-2037-1. View

4.
Grauer O, Nierkens S, Bennink E, Toonen L, Boon L, Wesseling P . CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer. 2007; 121(1):95-105. DOI: 10.1002/ijc.22607. View

5.
Heimberger A, Abou-Ghazal M, Reina-Ortiz C, Yang D, Sun W, Qiao W . Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008; 14(16):5166-72. DOI: 10.1158/1078-0432.CCR-08-0320. View